The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Open accessAbstract
B-cell lymphoma extra large (BCL-X L) is a well-validated cancer target. However, the on-target and dose-limiting thrombocytopenia limits the use of BCL-X L inhibitors, such as ABT263, as safe and effective anticancer agents. To reduce the toxicity of ABT263, we converted it into DT2216, a BCL-X L proteolysis-targeting chimera (PROTAC), that targets BCL-X L to the Von Hippel-Lindau (VHL) E3 ligase for degradation. We found that DT2216 was more potent against various BCL-X L-dependent leukemia and cancer cells but considerably less toxic to platelets than ABT263 in vitro because VHL is poorly expressed in platelets. In vivo, DT2216 effectively inhibits the growth of several xenograft tumors as a single agent or in combination with other chemotherapeutic agents, without causing appreciable thrombocytopenia. These findings demonstrate the potential to use PROTAC technology to reduce on-target drug toxicities and rescue the therapeutic potential of previously undruggable targets. Furthermore, DT2216 may be developed as a safe first-in-class anticancer agent targeting BCL-X L.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The use of a navitoclax PROTAC facilitated the rapid and specific degradation of BCL-2, resulting in apoptosis of cancer cells with less off-target lysis.”
From Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span (2021) · cites this paper as [76]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the therapeutic window of navitoclax is improved by utilizing an approach that degrades certain BCL-2 family members instead of just inhibiting their function (76).”
From Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span (2021) · cites this paper as [76]
The cited source says what the claim attributes to it.
In the citing paper
“several PROTACs have shown promising preclinical results in the treatment of hematologic malignancies [3, 4, 44]”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“DT2216 has shown promising antitumor activities in BCL-XL-dependent hematologic cancers as a single agent therapy and in multiple solid tumors when combined with conventional chemotherapy [8–10].”
From BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers (2022) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“Recently, our group has reported platelet-sparing targeting of BCL-XL by proteolysis targeting chimeras (PROTACs) exemplified by DT2216.”
From BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers (2022) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“This potentiates the antitumour activity of ABT263 while suppressing its side effects on platelets in which VHL is poorly expressed [120].”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [120]
The cited source says what the claim attributes to it.
In the citing paper
“Linkage of ABT263 to a von Hippel -Lindau (VHL) E3 ligasetargeting moiety results in degradation rather than inhibition of BCL-XL activity itself.”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [120]
The cited source says what the claim attributes to it.
In the citing paper
“DT2216, a VHL-recruiting BCL-xL PROTAC that achieved potent antitumor activity without the severe thrombocytopenia observed with navitoclax87”
From Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming (2026) · cites this paper as [87]
In the citing paper
“In 2019, Zhou’s team identified DT2216 (200), the first selective Bcl-xL degrader based on ABT263 (navitoclax), by linking ABT263 to VHL ligands (Table 4).”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [492]
In the citing paper
“In vivo, DT2216 effectively inhibited the growth of multiple xenograft tumors without causing significant thrombocytopenia.492”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [492]
In the citing paper
“DT2216 exhibited high potency against various Bcl-xL-dependent leukemia and cancer cells while demonstrating lower platelet toxicity than ABT263.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [492]
In the citing paper
“For instance, it was shown that a PROTAC that co-opts the E3 ligase VHL to induce the degradation of BCL-XL can spare the thrombocytopenia associated with systemic BCL-XL inhibition.72”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [72]
In the citing paper
“A remarkable example is the low expression of VHL in platelets”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [152]
In the citing paper
“degradation of BCL-xL by the VHL-recruiting PROTAC DT2216 (ref.152) was spared in platelets, thus resulting in reduced platelet-driven toxicity and an improved therapeutic index compared with a BCL-xL inhibitor78,153.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [152]
In the citing paper
“A number of PROTACs have been developed to target various POIs that are involved in the tumorigenesis and progression of hematologic malignancies, such as anaplastic lymphoma kinase (ALK) [5], Bcl-xL [4], BCR-ABL [6], Bruton’s tyrosine kinase (BTK) [7], BRD4 [8], CDK-6 [9], FMS-like tyrosine kinase-3 (FLT-3) [10], HDAC6 [11], and signal transducer and activator of transcription 3 (STAT3) [3].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [4]
In the citing paper
“Moreover, DT2216 potently degraded Bcl-xL protein and inhibited MOLT-4 T-ALL in vitro and in vivo.”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [4]
In the citing paper
“DT2216, a representative PROTAC that hijacks the VHL E3 ligase to achieve tissue/cell-selective degradation of Bcl-xL, was found to be more potent against Bcl-xL-dependent tumor cells and less toxic against platelets in comparison to conventional Bcl-xL inhibitors.”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [4]
In the citing paper
“Fourth, it is possible to achieve tumor-specific/selective degradation of a POI with PROTACs by using ligands for cell type- and/or tumor-specific/selective E3 ligases [2, 4].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [4]
In the citing paper
“Although numerous PROTACs have been generated in the past few years, only a few of them are tumor-selective to avoid normal tissue toxicity, including platelet sparing Bcl-xL PROTACs reported by us recently by taking advantage of the E3 ligases that are barely expressed in platelets [4, 60–63].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [4]
In the citing paper
“The prolonged depletion of a target by PROTACs may cause on-target toxicities if a POI is indispensable for normal functions [4].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [4]
In the citing paper
“Therefore, profiling the changes in global protein expression by proteomics will be helpful to appreciate the potential off-target toxicities of PROTACs [3, 4, 43].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [4]
In the citing paper
“Bcl-xL PROTACs discussed above are an example of this approach [4, 61–63].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [4]
In the citing paper
“Recently, we reported the first use of PROTAC technology to selectively target anti-apoptotic BCL-XL protein in tumor cells with reduced platelet toxicity by employing VHL or CRBN E3 ligases that are minimally expressed in platelets [34, 35, 36].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [35]
In the citing paper
“in the case of our BCL-XL PROTACs the prolonged degradation of BCL-XL may be advantageous because BCL-XL exhibits functional redundancy in normal tissues except platelets, and therefore its prolonged depletion accounts for better therapeutic efficacy [35, 80, 81].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [35]
In the citing paper
“Recently, we converted a dual inhibitor of BCL-XL and BCL-2, named ABT263 (or navitoclax), into selective VHL-based BCL-XL PROTACs, which provides further evidence that promiscuous inhibitors can be converted into target-specific PROTACs [35, 36].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [35]
In the citing paper
“we have shown that VHL is differentially expressed between tumor cells and platelets, which helped us to design platelet-sparing BCL-XL PROTACs [35, 36].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [35]
In the citing paper
“We were the first to report tumor-selective and platelet-sparing BCL-XL PROTACs by taking advantage of the E3 ligases that are barely expressed in platelets [34, 35, 36].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [35]
In the citing paper
“In addition, there are several other PROTAC drug candidates with promising preclinical data that can potentially be tested in clinical trials in the near future [1, 35, 40].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [35]
In the citing paper
“The development of PROTACs based on tissue-specific and tumor-selective E3 ligases could be one such potential strategy that can revolutionize the field of PROTACs as cancer therapeutics, as we recently demonstrated [35, 36].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [35]
In the citing paper
“Some of the PROTACs, such as PROTACs targeting BCL-XL and ALK [35, 105], have broad-spectrum antitumor activities, which can effectively kill leukemia and solid tumor cells in vitro and in xenograft models.”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
The Perseus computational platform for comprehensive analysis of (prote)omics data
Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., Mann, M., & Cox, J. (2016) · Nature Methods · doi:10.1038/nmeth.3901 · Cited by 8,803
Universal sample preparation method for proteome analysis
Wiśniewski, J. R., Zougman, A., Nagaraj, N., & Mann, M. (2009) · Nature Methods · doi:10.1038/nmeth.1322 · Cited by 8,352
A statistical model for identifying proteins by tandem mass spectrometry.
Nesvizhskii, A., Keller, A., Kolker, E., & Aebersold, R. (2003) · Analytical Chemistry · doi:10.1021/ac0341261 · Cited by 4,902
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
The Bcl-2 apoptotic switch in cancer development and therapy
Adams, J. M., & Cory, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210220 · Cited by 2,256
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Singh, R., Letai, A., & Sarosiek, K. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0089-8 · Cited by 2,111
Cited by
Sorted by citations
Items 301–400 of 698
Jaiswal, A., Jaiswal, A. S., Williamson, E. A., Gelfond, J. A. L., Zheng, G., Zhou, D., & Hromas, R. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04490-8 · Cited by 22
Self-citationChen, J., Jin, J., Gu, W., Zhao, Z., Hu, Y., Zhou, Y., Nagle, D. G., Xi, Q., Zhang, X., Sun, Q., et al. (2023) · Cancer Science · doi:10.1111/cas.15733 · Cited by 20
Self-citationFighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma
Simon, S. M. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00554-w · Cited by 21
Role of YY1 in the Regulation of Anti-Apoptotic Gene Products in Drug-Resistant Cancer Cells
Jung, M., Bui, I., & Bonavida, B. (2023) · Cancers · doi:10.3390/cancers15174267 · Cited by 21
Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Barghout, S. H. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200410082652 · Cited by 21
Therapy-induced senescence is finally escapable, what is next?
Saleh, T. (2024) · Cell Cycle · doi:10.1080/15384101.2024.2364579 · Cited by 21
Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma
Hughes, A. D., Pölönen, P., & Teachey, D. T. (2025) · Haematologica · doi:10.3324/haematol.2024.285643 · Cited by 20
Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms
Faryal, B., Abideen, Z. U., Irfan, M., Ahmed, H., Jalilov, F. S., Abduraximova, L., & Ashraf, G. A. (2026) · Biomolecules · doi:10.3390/biom16020325 · Cited by 24
Sejic, N., George, L. C., Tierney, R. J., Chang, C. W. T., Kondrashova, O., MacKinnon, R. N., Lan, P., Bell, A. I., Lessène, G., Long, H. M., et al. (2020) · PubMed Central · doi:10.1182/bloodadvances.2020002446 · Cited by 20
The Vital Role of Proteomics in Characterizing Novel Protein Degraders
Zhang, A. X., Cassidy, K. B., Dahl, G., Moreau, K., Pachl, F., & Zuhl, A. M. (2021) · SLAS DISCOVERY · doi:10.1177/2472555220985776 · Cited by 21
Drulă, R., Iluta, S., Gulei, D., Iuga, C. A., Dima, D. M., Ghiaur, G., Buzoianu, A. D., Ciechanover, A. J., & Tomuleasa, C. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100971 · Cited by 20
Emerging Target-Directed Approaches for the Treatment and Diagnosis of Microbial Infections
Almeida, M. C., da Costa, P. M., Sousa, E., & Resende, D. I. S. P. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01212 · Cited by 20
Discovery of PVD-06 as a Subtype-Selective and Efficient PTPN2 Degrader
Hu, L., Li, H., Qin, J., Yang, D., Liu, J., Luo, X., Ma, J., Luo, C., Ye, F., Zhou, Y., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01348 · Cited by 20
Recent Advances in Small Molecular Modulators Targeting Histone Deacetylase 6
Xiao, Y., & Zhang, X. (2020) · Future Drug Discovery · doi:10.4155/fdd-2020-0023 · Cited by 20
Self-citationTargeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
Floros, K. V., Jacob, S., Kurupi, R., Fairchild, C. K., Hu, B., Puchalapalli, M., Koblinski, J. E., Dozmorov, M. G., Boikos, S. A., Scaltriti, M., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03457-6 · Cited by 20
Lv, M., Hu, W., Zhang, S., He, L., Hu, C., & Yang, S. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215716 · Cited by 19
Negi, A., Kieffer, C., & Voisin‐Chiret, A. S. (2022) · ChemistrySelect · doi:10.1002/slct.202200981 · Cited by 19
Anti‐apoptotic protein BCL‐XL as a therapeutic vulnerability in gastric cancer
Wei, Y., Zhang, L., Wang, C., Li, Z., Luo, M., Xie, G., Yang, X., Li, M., Ren, S., Zhao, D., et al. (2023) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12330 · Cited by 19
Kim, Y.-J., Witwit, H., Cubitt, B., & de la Torre, J. C. (2021) · Journal of Virology · doi:10.1128/jvi.01399-21 · Cited by 19
Self-citationYamamoto, M., Sanomachi, T., Suzuki, S., Togashi, K., Sugai, A., Seino, S., Satō, A., Okada, M., & Kitanaka, C. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab148 · Cited by 20
Ubiquitination Enzymes in Cancer, Cancer Immune Evasion, and Potential Therapeutic Opportunities
Awan, A. B., Osman, M. J. A., & Khan, O. M. (2025) · Cells · doi:10.3390/cells14020069 · Cited by 18
Dual targeting, a new strategy for novel PARP inhibitor discovery
Wei, L., Wang, M., Wang, Q., & Han, Z. (2021) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2021.01100 · Cited by 18
Su, W., Tan, M., Wang, Z., Zhang, J., Huang, W., Song, H., Wang, X., Ran, H., Gao, Y., Nie, G., et al. (2023) · Angewandte Chemie · doi:10.1002/ange.202218128 · Cited by 18
PROTAC targeting cyclophilin A controls virus-induced cytokine storm
Li, H., Yang, W., Li, H., Bai, X., Zhang, H., Fan, W., Liu, W., & Sun, L. (2023) · iScience · doi:10.1016/j.isci.2023.107535 · Cited by 19
Xu, W., Zhao, T., Chen, H., Huang, N., Gong, H., Zhang, J., Yu, Y., Li, T., Zhang, G., Gong, C., et al. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115045 · Cited by 20
Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins
Pal, P., Zhang, P., Poddar, S. K., & Zheng, G. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2116311 · Cited by 18
Self-citationMitochondrial priming and response to BH3 mimetics in “one-two punch” senogenic-senolytic strategies
López, J., Llop‐Hernández, À., Verdura, S., Serrano‐Hervás, E., Martinez‐Balibrea, E., Bosch‐Barrera, J., Teixidor, E., López‐Bonet, E., Martín-Castillo, B., Josep Sardanyés, A., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02379-y · Cited by 20
De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer
Zhang, H., Santana-Codina, N., Yu, Q., Poupault, C. L., Campos, C., Qin, X., Sindoni, N., Ciscar, M., Padhye, A., Kuljanin, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61242-x · Cited by 19
Liu, Y., Zhang, X., Chen, X., & Zhang, F. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2025.123621 · Cited by 20
Self-citationFTO degrader impairs ribosome biogenesis and protein translation in acute myeloid leukemia
Li, W., Zhao, Y., Wu, D., Chen, Z., Qing, Y., Yang, F., Ji, F., Zhang, L., Sau, L., Chen, J., et al. (2025) · Science Advances · doi:10.1126/sciadv.adv7648 · Cited by 17
Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
Li, Q., Zhou, L., Qin, S., Huang, Z., Li, B., Li, B., Yang, M., Nice, E. C., Zhu, H., & Huang, C. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115447 · Cited by 17
Carpenter, V. J., Patel, B. B., Riccardo Autorino, B., Smith, S. C., Gewirtz, D. A., & Saleh, T. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188424 · Cited by 17
Jang, J., To, C., Clercq, D. J. H. D., Park, E., Ponthier, C. M., Shin, B. H., Mushajiang, M., Nowak, R. P., Fischer, E. S., Eck, M. J., et al. (2020) · Angewandte Chemie · doi:10.1002/ange.202003500 · Cited by 17
Racioppo, B., Pechalrieu, D., Abegg, D., Dwyer, B. G., Ramseier, N. T., Hu, Y., & Adibekian, A. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c17827 · Cited by 18
New PROTAC Designs for Targeted Protein Degradation in 2021–2025: Novel E3 Ligases and Pre-PROTACs
Peng, W., Pan, X., Wang, S., Huang, G., & Qian, Y. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03330 · Cited by 19
Self-citationDiscovery, development and application of drugs targeting BCL-2 pro-survival proteins in cancer
Lee, E. F., & Fairlie, W. D. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210749 · Cited by 18
Small molecule SJ572946 activates BAK to initiate apoptosis
Sekar, G., Singh, G., Qin, X., Guibao, C. D., Schwam, B., Inde, Z., Grace, C. R., Zhang, W., Slavish, P. J., Lin, W., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105064 · Cited by 15
Self-citationFitzgerald, M.-C., O’Halloran, P. J., Kerrane, S. A., Chonghaile, T. N., Connolly, N. M. C., & Murphy, B. M. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06231-y · Cited by 16
Nie, X., Zhao, Y. Q., Tang, H., Zhang, Z., Liao, J., Almodóvar‐Rivera, C. M., Sundaresan, R., Xie, H., Guo, L., Wang, B., et al. (2023) · ChemBioChem · doi:10.1002/cbic.202300685 · Cited by 17
Mukerjee, N., Maitra, S., Ghosh, A., Sengupta, T., Alexiou, A. T., Subramaniyan, V., & Anand, K. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.3c04537 · Cited by 16
Potency-Enhanced Peptidomimetic VHL Ligands with Improved Oral Bioavailability
Wu, H., Murray, J. M., Ishisoko, N., Frommlet, A., Deshmukh, G. S., DiPasquale, A. G., Mulvihill, M. M., Zhang, D., Quinn, J. G., Blake, R. A., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02203 · Cited by 16
Urbina, A., Hallatt, A. J., Robertson, J., & Ciulli, A. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2446232 · Cited by 17
Modeling PROTAC degradation activity with machine learning
Ribes, S., Nittinger, E., Tyrchan, C., & Mercado, R. (2024) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2024.100104 · Cited by 15
Manen-Freixa, L., & Antolín, A. A. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2376643 · Cited by 15
Grubb, T. M., Maganti, S., Krill-Burger, J. M., Fraser, C. S., Stransky, L. A., Radivoyevitch, T., Sarosiek, K. A., Vázquez, F., Kaelin, W. G., & Chakraborty, A. A. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0669 · Cited by 18
Yan, W., Pan, B., Shao, J., Lin, H.-K., & Li, H. (2022) · ACS Omega · doi:10.1021/acsomega.2c00245 · Cited by 15
Targeted degradation of specific TEAD paralogs by small molecule degraders
Chen, H., Gridnev, A., Schlamowitz, N. S., Hu, W., Dey, K., Zheng, G., & Misra, J. R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37829 · Cited by 14
Self-citationDesign, synthesis, and biological evaluation of Wee1 kinase degraders
Zhu, S., Liu, J., Xiao, D., Wang, P., Ma, J., Hu, X., Fu, J., Zhou, Y., Li, J. X., & Lu, W. P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114786 · Cited by 15
Zhang, Z., Yang, K., & Zhang, H. (2022) · Cancers · doi:10.3390/cancers14225655 · Cited by 16
The Potent and Paradoxical Biology of Cellular Senescence in Cancer
Romesser, P. B., & Lowe, S. W. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-124434 · Cited by 15
PROteolysis‐Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives
Vicente, A. T. S., & Salvador, J. A. R. (2024) · MedComm · doi:10.1002/mco2.575 · Cited by 14
Wang, T., Shi, X., Xu, X., Zhang, J., Ma, Z., Meng, C., Jiao, D., Wang, Y., Chen, Y., He, Z., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123129 · Cited by 14
Pedrucci, F., Pappalardo, C., Marzaro, G., Ferri, N., Ferlin, A., & Toni, L. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126630 · Cited by 14
MDM2-BCL-XL PROTACs enable degradation of BCL-XL and stabilization of p53
Chang, M., Gao, F., Chen, J., Gnawali, G. R., & Wang, W. (2022) · Acta Materia Medica · doi:10.15212/amm-2022-0022 · Cited by 18
Zhao, X., Chen, Y., Su, H., & Zhang, L. (2023) · Interdisciplinary medicine · doi:10.1002/inmd.20230004 · Cited by 14
Chimera induced protein degradation: PROTACs and beyond
Yin, L., & Hu, Q. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112494 · Cited by 14
An Update on Clinically Advanced PROTAC Degraders and Their Synthesis
Acharyya, R. K., Kothapalli, Y., Yarlagadda, S., De, C. K., Allu, S. R., Roy, J., & Rej, R. K. (2025) · Molecules · doi:10.3390/molecules31010033 · Cited by 13
What does BCL-2 do? From new molecular insights to the clinical implications
Croce, C. M., Tait, S. W. G., García‐Sáez, A. J., Villunger, A., Letai, A. G., Walter, H. S., Dyer, M. J. S., Green, D. R., Shi, Y., & Melino, G. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-025-01607-3 · Cited by 14
Targeting intracellular proteins with cell type-specific functions for cancer immunotherapy
Carelock, M. E., Master, R. P., Kim, M., Jin, Z., Wang, L. A., Maharjan, C. K., Hua, N., De, U., Kolb, R. H., Xiao, Y., et al. (2023) · Life Medicine · doi:10.1093/lifemedi/lnad019 · Cited by 13
Self-citationAn updated patent review of Mcl-1 inhibitors (2020–2022)
Liu, J., Yin, F., Wang, Z., Song, T., & Zhang, Z. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2219394 · Cited by 13
Tang, G. L. Q., Lai, J. X. H., & Pervaiz, S. (2023) · Haematologica · doi:10.3324/haematol.2023.283730 · Cited by 15
Selective induction of programmed cell death using synthetic biology tools
Shkarina, K., & Brož, P. (2023) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2023.07.012 · Cited by 16
Gong, Q., Wang, H., Zhou, M., Zhou, L., Wang, R., & Li, Y. (2023) · Medicinal Research Reviews · doi:10.1002/med.21999 · Cited by 13
Srinivasan, M. K., Premnath, B. J., Parimelazhagan, R., & Nalini, N. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4062 · Cited by 13
Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia
Wu, T., Hu, J., Zhao, X., Zhang, C., Dong, R., Hu, Q., Xu, H., Shen, H., Zhang, X., Zhang, Y., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00335 · Cited by 14
Self-citationParalogue-Selective Degradation of the Lysine Acetyltransferase EP300
Chen, X., Crawford, M. C., Xiong, Y., Shaik, A. B., Suazo, K. F., Bauer, L. G., Penikalapati, M. S., Williams, J. H., Huber, K., Andressen, T., et al. (2024) · JACS Au · doi:10.1021/jacsau.4c00442 · Cited by 12
Luo, M., Yang, J., Schäffer, A. A., Chen, C., Liu, Y., Chen, Y., Lin, C., Diao, L., Zang, Y., Lou, Y., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0827 · Cited by 14
Biphenyl-dihydrothiazole-cyclized peptide libraries for peptide ligand and drug discovery
Liu, J.-J., Sun, X., Zhuang, J., Liu, Z., Xu, C., Wu, D., & Wu, C. (2025) · Science China Chemistry · doi:10.1007/s11426-024-2291-x · Cited by 14
VIPER-TACs leverage viral E3 ligases for disease-specific targeted protein degradation
Mangano, K., Guenette, R. G., Hill, S., Li, S., Liu, J. J., Nadel, C. M., Archunan, S., Sadhukhan, A., Kapoor, R., Yang, S. W., et al. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.02.002 · Cited by 14
Cancer and aging: A call to action
Braithwaite, D., Anton, S. D., Mohile, S. G., DeGregori, J. V., Gillis, N., Zhou, D., Bloodworth, S., Pahor, M., & Licht, J. D. (2022) · Aging and Cancer · doi:10.1002/aac2.12055 · Cited by 13
Self-citationBarillé‐Nion, S., Lohard, S., & Juin, P. P. (2020) · Biomolecules · doi:10.3390/biom10081109 · Cited by 16
Review of the impact of fragment-based drug design on PROTAC degrader discovery
Chen, P., Li, Q., & Lei, X. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117539 · Cited by 13
Huber, A. D., Lin, W., Poudel, S., Miller, D. J., & Chen, T. (2024) · Structure · doi:10.1016/j.str.2024.09.016 · Cited by 12
Advancing target validation with PROTAC technology
Spitz, M. L., Kashkush, A., & Benhamou, R. I. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2490248 · Cited by 12
PROTAC: A Novel Technology for Drug Development**
Li, J., & Liu, J. (2020) · ChemistrySelect · doi:10.1002/slct.202003162 · Cited by 13
Expression and purification of functional recombinant CUL2•RBX1 from E. coli
Diaz, S., Li, L., Wang, K., & Liu, X. (2021) · Scientific Reports · doi:10.1038/s41598-021-90770-x · Cited by 14
Self-citationBcl‐xL as prognostic marker and potential therapeutic target in cholangiocarcinoma
Hoffmeister‐Wittmann, P., Möck, A., Nichetti, F., Korell, F., Heilig, C. E., Scherr, A., Günther, M., Albrecht, T., Kelmendi, E., Xu, K., et al. (2022) · Liver International · doi:10.1111/liv.15392 · Cited by 12
Engineered PD-L1 nanoregulators for enhanced tumor immunotherapy
Inam, M., Ren, K., Shen, B., Zhou, F., Tian, L., Liu, J., & Sun, X. J. (2025) · Biomaterials Science · doi:10.1039/d5bm00748h · Cited by 11
Grinshpun, A. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000972 · Cited by 11
Saleem, H. N., Kousar, S., Jiskani, A. H., Sohail, I., Faisal, A., & Saeed, M. (2023) · Archiv der Pharmazie · doi:10.1002/ardp.202300292 · Cited by 11
Precision oncology revolution: CRISPR-Cas9 and PROTAC technologies unleashed
Kanbar, K., Darzi, R. E., & Jaalouk, D. E. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1434002 · Cited by 17
Zhou, C., Sun, C., Huang, M. L., Tang, X., Pi, L., & Li, C. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00815 · Cited by 12
Proteolysis‐Targeting Chimera (PROTAC): A Revolutionary Tool for Chemical Biology Research
Pan, M., Fu, Z., Hou, H., Yang, C., & Li, J. (2025) · Small Methods · doi:10.1002/smtd.202500402 · Cited by 13
Molecular mechanisms by which splice modulator GEX1A inhibits leukaemia development and progression
Sellin, M., Mack, R. M., Rhodes, M. C., Zhang, L., Berg, S. A., Joshi, K., Liu, S., Wei, W., Breslin, P., Larsen, P., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01796-5 · Cited by 11
Bcl-x short-isoform is essential for maintaining homeostasis of multiple tissues
Keller, M. A., Huang, C.-Y., Ivessa, A., Singh, S., Romanienko, P. J., & Nakamura, M. (2023) · iScience · doi:10.1016/j.isci.2023.106409 · Cited by 11
Bifunctional robots inducing targeted protein degradation
Sobhia, M. E., Kumar, H., & Kumari, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115384 · Cited by 11
Fischer, S., Trinh, V. T., Simon, C., Weber, L. M., Forné, I., Nist, A., Bange, G., Abendroth, F., Stiewe, T., Steinchen, W., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.05.012 · Cited by 11
BCL‐XL exerts a protective role against anemia caused by radiation‐induced kidney damage
Brinkmann, K., Waring, P., Glaser, S. P., Wimmer, V. C., Cottle, D. L., Tham, M. S., Nhu, D., Whitehead, L. W., Delbridge, A. R. D., Lessène, G., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2020105561 · Cited by 10
Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-XL and BCL-2
Roy, M. J., Vom, A., Okamoto, T., Smith, B. J., Birkinshaw, R. W., Yang, H. J., Abdo, H., White, C. A., Segal, D., Huang, D. C. S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01771 · Cited by 11
Qin, X., Presser, A. G., Johnson, L., Matoba, Y., Shay, B., Xu, W., Choiniere, J., Fraser, C., Garbicz, F., Spetz, J. K. E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.24.661170 · Cited by 11
Self-citationTrono, P., Masi, I., Ottavi, F., & Rosanò, L. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-025-01211-0 · Cited by 13
Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges
Ajufo, H. O., Waksal, J. A., Mascarenhas, J. O., & Rampal, R. K. (2023) · Therapeutic Advances in Hematology · doi:10.1177/20406207231177282 · Cited by 10
Ubiquitin recruiting chimera: more than just a PROTAC
Grigoreva, T. A., Novikova, D., Melino, G., Barlev, N. A., & Tribulovich, V. G. (2024) · Biology Direct · doi:10.1186/s13062-024-00497-8 · Cited by 12
PROTAC as a novel anti-cancer strategy by targeting aging-related signaling
Peng, Y., Liu, D., Huang, D., Inuzuka, H., & Liu, J. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.09.004 · Cited by 10
Wang, Z., Yue, S., Chen, X., Li, J., Zhu, P., Chen, H., Qiu, F., Xie, D., Liang, Y., Li, D., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01228 · Cited by 11
Alternative splicing of BCL‑X and implications for treating hematological malignancies (Review)
Chen, W., & Li, J. (2021) · Oncology Letters · doi:10.3892/ol.2021.12931 · Cited by 10
Paternot, S., Raspé, E., Meiller, C., Tarabichi, M., Assié, J., Libert, F., Remmelink, M., Bisteau, X., Pauwels, P., Blum, Y., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13351 · Cited by 10
Xu, H., Hu, R., & Zhao, Z. (2023) · Molecular Biology and Evolution · doi:10.1093/molbev/msad253 · Cited by 11
mRNA PROTACs: engineering PROTACs for high‐efficiency targeted protein degradation
Xue, X., Zhang, C., Li, X., Wang, J., Zhang, H., Feng, Y., Xu, N., Li, H., Tan, C., Jiang, Y., et al. (2024) · MedComm · doi:10.1002/mco2.478 · Cited by 9
Marca, J. E. L., Kelly, G. L., Strasser, A., & Diepstraten, S. T. (2024) · Developmental Cell · doi:10.1016/j.devcel.2024.06.018 · Cited by 9
Metadata
- Authors
- Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., Pei, J., Zhang, W., Sharma, A., McCurdy, C. R., Kuruvilla, V. M., Baran, N., Ferrando, A. A., Kim, Y.-M., Rogojina, A., Houghton, P. J., Huang, G., Hromas, R., Konopleva, M., Zheng, G., & Zhou, D.
- Affiliations
- University of Florida (US)
- The University of Texas MD Anderson Cancer Center (US)
- Columbia University (US)
- Children's Hospital Los Angeles (US)
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- Zheng, Guangrong
- Zhou, Daohong
- ORCID
- Khan, Sajid
- Zhang, Xuan
- Lv, Dongwen
- Zhang, Qi
- He, Yonghan
- Zhang, Peiyi
- Liu, Xingui
- Thummuri, Dinesh
- Yuan, Yaxia
- Pei, Jing
- Zhang, Weizhou
- Sharma, Abhisheak
- McCurdy, Christopher R.
- Kuruvilla, Vinitha M.
- Baran, Natalia
- Ferrando, Adolfo A.
- Kim, Yong-mi
- Houghton, Peter J.
- Huang, Guangcun
- Hromas, Robert
- Konopleva, Marina
- Zheng, Guangrong
- Zhou, Daohong
- Venue
- Nature Medicine
- Published
- 2019-12
- Volume
- 25
- Issue
- 12
- Pages
- 1938-1947
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC6898785
- OpenAlex
- W2990669650
- Cited by
- 688
- References
- 63
- Citations by year
- 2026: 98 · 2025: 127 · 2024: 116 · 2023: 103 · 2022: 105 · 2021: 83 · 2020: 55
- FWCI
- 20.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH
- CPRIT
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- Bcl-xL, PROTACs, VHL E3 ubiquitin ligase, thrombocytopenia, navitoclax, platelet toxicity, leukemia, tumor xenografts, BCL-2 inhibitor, on-target toxicity
- MeSH terms
- Aniline Compounds, Animals, Antineoplastic Agents, Blood Platelets, Humans, Sulfonamides, Thrombocytopenia, Gene Expression Regulation, Neoplastic, bcl-X Protein, Mice, Von Hippel-Lindau Tumor Suppressor Protein, Proteolysis, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
